ArticleCurrent research in toxicology2026
Identifying androgen receptor antagonists using a metabolically competent high-throughput screening assay.
Article in Current research in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgen receptor (AR) is a nuclear receptor with a well-established role in sexual function and development. Modifications in AR can lead to endocrine disruption, cancer, and other diseases, making it imperative to identify compounds that influence these changes. AR modulators have been identified using immortalized cell lines in a high-throughput screening assay. However, most of these methods do not incorporate metabolism, leading to misclassification of compounds that normally require it to become AR modulators. Metabolism transforms exogenous parent compounds into metabolites that are easier to excrete, and normally less active than the parent. However, some metabolites modulate AR more effectively than the parent compound. Incorporating metabolism into a large compound screen can identify active metabolites as potential AR modulators. In this study, we optimized a high-throughput screening assay that included rat liver microsomes (RLM) as an exogenous metabolic system to detect AR antagonists. A robotic screen of the LOPAC library + 88 Tox21 compounds (a total of 1365 unique compounds) was then performed to validate the assay and identify any bioactivated AR modulators within the test library. Fifty-five compounds were identified as potential AR antagonists; 9 compounds out of these 55 compounds were found to have significant potency shifts between RLM free and RLM assays, suggesting the necessity of metabolism for their AR activity. A concurrent assay using heat-inactivated RLM was conducted to discern the true activity of each compound. Metabolic stability assays were also performed on the top compounds to clarify their ability to transition from parent to metabolite using RLM. Four compounds were identified as novel parent compounds requiring metabolism to become more potent AR antagonists. However, only 4,5-dianilinophthalimide (DAPH) displayed a clear concentration-response curve with a more potent IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.